Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
NCT01137851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3940
Last updated 2010-10-01
Summary
The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-11-30
- Primary Completion
- 2010-09-30
- Completion
- 2010-09-30
More Related Trials
-
Factors Associated With Biologic DMARD Switching
NCT02346942 ·Status: COMPLETED
-
Impact Of RA Therapy Compliance On Patient-Reported Outcomes
NCT01438892 ·Status: COMPLETED
-
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
NCT00124449 ·Status: COMPLETED ·Phase: PHASE2
-
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)
NCT01078116 ·Status: COMPLETED
-
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT02353780 ·Status: TERMINATED ·Phase: PHASE4
-
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
NCT01021735 ·Status: COMPLETED ·Phase: PHASE4
-
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
NCT01351480 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
NCT01679951 ·Status: TERMINATED ·Phase: PHASE2
-
Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)
NCT01489384 ·Status: UNKNOWN
-
Post-marketing Study Assessing the Long-Term Safety of Abatacept
NCT02169544 ·Status: COMPLETED
-
A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients
NCT04047121 ·Status: COMPLETED
-
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
NCT01333878 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
NCT01225393 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)
NCT01088321 ·Status: COMPLETED
-
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
NCT01682512 ·Status: TERMINATED ·Phase: PHASE3
-
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
NCT01636817 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
NCT03882008 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)
NCT01181050 ·Status: COMPLETED ·Phase: PHASE2
-
REMission INDuction in Very Early Rheumatoid Arthritis
NCT02935387 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)
NCT00482417 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
NCT01712178 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Abatacept in Rheumatoid Arthritis Participants
NCT03696173 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
NCT01853033 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
NCT04985812 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis
NCT01282255 ·Status: COMPLETED ·Phase: PHASE2